Management Team

André Choulika, Ph.D., founder of Cellectis SA, has served as Chief Executive Officer since the company's inception. Dr. Choulika is a pioneer in the analysis and use of Meganucleases to modify complex genomes. He has made many of the critical observations in the field and is an author of the most significant patents on the use of Meganucleases in vivo. Dr. Choulika received a Ph.D. in Molecular Virology form University of Paris VI / Institut Pasteur. Dr. Choulika has made post-doctoral studies at the Harvard Medical School within the department of Molecular Medicine of Boston's Children's Hospital.

David J.D. Sourdive, Ph.D., Vice President Corporate Development and Chief Operations' Officer, co-founded Cellectis SA with Dr Choulika, and has served as Director since 2000. Prior to inception of the company, Dr Sourdive was the head of Biotechnology Laboratory at the Centre d'Etudes du Bouchet (French Ministry of Defense). At the same time, Dr Sourdive was heading a research group in Immunology at the Pasteur Institute. Dr. Sourdive attended Ecole Polytechnique and received a Ph.D. in Molecular Virology form University of Paris VII/ Institut Pasteur. Dr Sourdive then applied recombination tracking technologies to anti-viral immune memory, at the Emory University Vaccine Center in Atlanta.

Frédéric Pâques, Ph.D., Chief Scientific Officer, joined Cellectis in October 2001. He has served as Chief Scientific Officer since June 2002. Dr. Pâques is a world expert in DNA recombination mechanisms. He received his Ph. D. in 1994 from University of Paris. Dr Pâques joined Brandeis University (Waltham, Ma), where he produced seminal work on recombination in yeast, before being appointed to the CNRS in Paris (France).

Delphine Jay, Chief Administrative Officer, joined Cellectis in January 2001. She started her career in the optical industry. Delphine Jay joined the Head Office of an architectural firm to set up the administrative and financial management. After a year at MCI Worldcom as quantity surveyor in charge of international data centers construction, Delphine Jay joined Cellectis.

Marc Le Bozec, Chief Financial Officer, joined Cellectis in October 2006. He was Chief Operating Officer of Alfact Innovation (France). He has more than 10 years experience in the biotech sector as consultant (Arthur D. Little, Paris office) and as founder and Chairman & CEO of BioProtein Technologies (France), a biotech company dedicated to the production of recombinant proteins in the milk of transgenic animals. He is graduated from HEC School of Management, Paris.